The NanoTherapeutics team aims to exploit the properties of nanoparticles and their interactions with cells and tissues for the development of safe and effective medicines, using clinically-relevant disease models. Our mission is to further the progress of nanomedicine toward clinical translation, particularly in disease areas failed by conventional drugs and therapies.
NanoTherapeutics Research Projects
2D nanomaterials for enhanced cancer immunotherapies
We are investigating the application of graphene and other 2D nanomaterials for more targeted and effective cancer immunotherapies. Current immunotherapy approaches are often limited by their inability to incite effective systemic immune responses and can be associated with dose-limiting off-target immune toxicities. Using 2D nanomaterials as a delivery system we hope to provide more targeted and synchronous induction of innate and adaptive immunity to overcome these limitations.
Developing advanced local drug delivery systems for infiltrating brain tumours
We are exploring nanoparticles and their advantageous distribution in tumour tissue for the development of local drug delivery systems. For this work we focus on using advanced orthotopic cancer models and delivery systems that are the most clinically relevant for each case. The versatility of nanoparticles enables exploration of different therapeutic modalities alone or in combination (chemotherapy, radiotherapy and immunotherapy).
Modulating the fate and behaviour of cells in vivo
We are investigating approaches to directly modulate cell fate and behaviour in vivo for applications in regenerative medicine. In this project we utilise a gene therapy approach to directly modulate cells in situ to support the more effective repair of diseased or injured tissue.
TEAM MEMBERS
Dr. Thomas Kisby
Senior ResearcherNanoTherapeutics Team Leader
Dr. Lorena Fernandes
Research Associate
Ms. Maria Stylianou
PhD Student
Ms. Mang Xu
PhD Student
Ms. Lydia Thompson
PhD Student
Dr. Yu Siong Ho
Research Lab Manager & Research Assistant
NanoTherapeutics PUBLICATIONS
FILTER
COVERS
EDITORIAL
Professor Kostarelos founded in 2006 and is still acting as the Senior Editor the journal Nanomedicine (Future Medicine, London).
Nanomedicine was the first medicine-oriented journal in the field, addressing the important advances and challenges towards the clinical use of nanoscale-structured materials and devices.
Professor Kostarelos also sits on the Editorial Advisory Board of:
Funding
Collaborators
PART OF
